NICOLE SPOONER: Open Payments
NPI 1508186644 · BERKELEY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,254 in 72 payments from 15 companies in 2025. Trend: 2023 $3,406 · 2024 $5,070 · 2025 $2,254
Food & beverage: $2,254
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 10 | $418 |
| Galderma Laboratories, L.P. | 8 | $318 |
| LEO Pharma Inc. | 17 | $265 |
| PFIZER INC. | 7 | $255 |
| ABBVIE INC. | 6 | $247 |
| Janssen Biotech, Inc. | 5 | $143 |
| Novartis Pharmaceuticals Corporation | 3 | $104 |
| REVANCE THERAPEUTICS, INC. | 2 | $103 |
| Incyte Corporation | 3 | $77 |
| Arcutis Biotherapeutics, Inc. | 3 | $73 |
Products named: DUPIXENT, NEMLUVIO, LITFULO, ADBRY, TREMFYA, BOTOX, DAXXIFY, OPZELURA.
Industry payments across CA — which companies pay providers there.
